Shares of Sarepta Therapeutics Inc soared 31% on Friday after U.S. regulators shocked Wall Street by approving the company's treatment for a muscle-wasting disorder less than four months after rejecting the drug over safety concerns.
Shares of Sarepta Therapeutics Inc soared 32% on Friday after U.S. regulators shocked Wall Street by reversing their rejection of its muscle-wasting disorder therapy less than four months ago, to allow the drug's immediate launch.
Merck & Co Inc said on Monday it would buy ArQule Inc for $2.7 billion, as it looks to tap into the drug developer's experimental blood cancer therapy that targets genetic mutations.
Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously rejected hedge fund Elliott Management's push for a "proactive sale" process of the entire company because it would not be in the best interest of shareholders.
Privately held drug developer Enzyvant said on Thursday the U.S. Food and Drug Administration declined to approve its regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about its manufacturing.
Abarca, a small Puerto Rico-based pharmacy benefits manager, said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel, if patients discontinue taking it after three months.
The use of tear gas to control crowds of protesters in the Chinese-ruled city of Hong Kong could have dangerous effects on health and the environment, a group of academics warns.
(Reuters Health) - Americans today are expected to live shorter lives than just a few years ago, in contrast with trends seen in other developed nations, and rising deaths from alcohol-related liver disease may be partly to blame, researchers say.
Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.